We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic (HOLX) Advances While Market Declines: Some Information for Investors
Read MoreHide Full Article
In the latest trading session, Hologic (HOLX - Free Report) closed at $61.27, marking a +0.67% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.23%. On the other hand, the Dow registered a loss of 0.91%, and the technology-centric Nasdaq increased by 0.1%.
The the stock of medical device maker has fallen by 5.7% in the past month, leading the Medical sector's loss of 10.2% and the S&P 500's loss of 12.13%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on May 1, 2025. It is anticipated that the company will report an EPS of $1.02, marking a 0.97% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1 billion, indicating a 1.56% decrease compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.28 per share and a revenue of $4.08 billion, indicating changes of +4.9% and +1.29%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. At present, Hologic boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Hologic currently has a Forward P/E ratio of 14.23. This represents a discount compared to its industry's average Forward P/E of 23.48.
Meanwhile, HOLX's PEG ratio is currently 2.02. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HOLX's industry had an average PEG ratio of 2.14 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 80, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Hologic (HOLX) Advances While Market Declines: Some Information for Investors
In the latest trading session, Hologic (HOLX - Free Report) closed at $61.27, marking a +0.67% move from the previous day. The stock's change was more than the S&P 500's daily loss of 0.23%. On the other hand, the Dow registered a loss of 0.91%, and the technology-centric Nasdaq increased by 0.1%.
The the stock of medical device maker has fallen by 5.7% in the past month, leading the Medical sector's loss of 10.2% and the S&P 500's loss of 12.13%.
Analysts and investors alike will be keeping a close eye on the performance of Hologic in its upcoming earnings disclosure. The company's earnings report is set to go public on May 1, 2025. It is anticipated that the company will report an EPS of $1.02, marking a 0.97% fall compared to the same quarter of the previous year. Meanwhile, the latest consensus estimate predicts the revenue to be $1 billion, indicating a 1.56% decrease compared to the same quarter of the previous year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.28 per share and a revenue of $4.08 billion, indicating changes of +4.9% and +1.29%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Hologic. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.03% lower. At present, Hologic boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Hologic currently has a Forward P/E ratio of 14.23. This represents a discount compared to its industry's average Forward P/E of 23.48.
Meanwhile, HOLX's PEG ratio is currently 2.02. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. HOLX's industry had an average PEG ratio of 2.14 as of yesterday's close.
The Medical - Instruments industry is part of the Medical sector. With its current Zacks Industry Rank of 80, this industry ranks in the top 33% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.